Free Trial
→ Elon says the ‘S’ word (From Paradigm Press) (Ad)tc pixel
NASDAQ:PDSB

PDS Biotechnology Q3 2026 Earnings Date & Estimates

PDS Biotechnology logo
$1.13 -0.17 (-13.08%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.11 -0.02 (-2.12%)
As of 10/16/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PDS Biotechnology is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from PDS Biotechnology in Q3 2026

PDS Biotechnology is expected to post earnings of -$0.11 per share. In the same quarter a year earlier PDS Biotechnology reported -$0.19 per share. PDS Biotechnology last reported on August 13, 2026, posting -$0.18 per share and missing the -$0.13 consensus estimate. PDS Biotechnology has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.11
Prior-Year EPS
-$0.19

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.18 (Missed by -$0.05)
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

PDS Biotechnology Q3 2026 Earnings FAQ

PDS Biotechnology (NASDAQ:PDSB) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

PDS Biotechnology's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect PDS Biotechnology to post earnings of -$0.11 per share for Q3 2026.

PDS Biotechnology Earnings Headlines

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375413/37149/en/pds-biotech-to-host-key-opinion-leader-event-on-pds0301-for-the-treatment-of-advanced-colorectal-cancer-with-liver-metastases.html
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and ...
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-cancer-in-jama-1036563484
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 18 at 1:00 AM  |  Weiss Ratings (Ad)
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366230/37149/en/pds-biotech-announces-publication-of-versatile-002-phase-2-clinical-trial-results-of-pds0101-with-pembrolizumab-in-hpv16-positive-recurrent-and-or-metastatic-r-m-head-and-neck-canc.html
PDS Biotechnology Highlights Progress in Colorectal Cancer Programs
September 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pds-biotechnology-highlights-progress-in-colorectal-cancer-programs?utm_source=marketbeat.com&utm_medium=referral
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pds-biotechnology-pdsb-stock-fair-211230200.html
See More PDS Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PDS Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PDS Biotechnology and other key companies, straight to your email.

About PDS Biotechnology

PDS Biotechnology (NASDAQ:PDSB) (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers. The company is also advancing additional vaccine and immunotherapy candidates based on its Versamune platform.

Founded in 2005 and headquartered in Florham Park, New Jersey, PDS Biotech conducts development activities through clinical research programs and collaborations. Its programs are investigational and remain subject to clinical testing and regulatory review. The company is led by President and Chief Executive Officer Frank Bedu-Addo.

View PDS Biotechnology Profile
Earnings Tools